Allt inom mfn_news

Nomination Committee for the 2026 Annual General Meeting in Nanexa AB (publ)

The Nomination Committee for the Annual General Meeting 2026 in Nanexa AB (publ) has been appointed.

Nanexa publishes year-end report and Q4 report 2025

The year ended strongly with an important milestone; the license and option agreement with Moderna, which is an important validation of our technology and has created favourable conditions for 2026 and beyond